Original Source: Bottled Water Market Bottled water contributes a major share in the global soft drinks industry. Increasing awareness among people about consuming safe water is increasing demand for bottled water worldwide. Urbanization and increasing economic stability in developing countries such as China, India and Mexico is also generating demand for bottled water in this part of the world. Other factors influencing growth of bottled water are availability of convenience packaging and inability of the governments to provide safe drinking water. The report segments the global bottled water market by products and geographies, estimates revenues for the next five years and analyzes emerging trends and opportunities for the same. Browse in-depth ToC on Global Bottled Water Market: Critical Success Factors and Global Forecast (2010-2015) About: M&M Banking and Financial Services Practice recognize the challenges that financial institutions face while bringing the right products to market. Our reports and consulting practice provides a unique perspective allowing financial institutions to understand and strategize to achieve their product goals. Through a mix of case studies, primary research, and business modeling we provide a 360° view to identify how our clients can create, capture, and retain the value of their products and outthink the competition. Contact:
Buy Now: Bottled Water Market
Early buyers will receive 10% customization of reports
http://www.marketsandmarkets.com/Market-Reports/bottled-water-265.html
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategic advisory reports and serve as a business intelligence partner to Fortune 500 companies across the globe. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.
Ms. Sunita
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com
http://www.marketsandmarkets.com
http://marketsandmarkets.wordpress.com/
http://marketsandmarkets.blogspot.com/
New Report Global Bottled Water Market: Critical Success Factors and Global Forecast (2010-2015) Published By MarketsandMarkets
Posted by
Unknown
on
categories:
2010,
2015,
Bottled Water,
Bottled Water Market,
Industry Analysis,
Market Research,
market research reports,
Market Share,
market size,
research
|
Original Source: Anti Nicotine Therapies Smoking cessation products are gaining popularity in both OTC and prescription products market segments. Increasing burden on healthcare system due to deteriorating quality of life because of smoking and several side effects associated with the current smoking cessation marketed products, builds up the need of novel products with better efficacy in this market. Besides this, there is also an opportunity fro well tolerated prescribed smoking cessation products. The report analyses several anti nicotine therapies (OTC and prescription) present in the market, their sales forecast (2009-2015) along with the market share of leading products and players. It also provides the comprehensive review of the market trends constituting the major opportunities, drivers and restrains of the growth of this market. The report will also detail the competitive landscape with respect to recent market and product developments. Browse in-depth ToC on Anti Nicotine Therapies (2010 – 2015) About: M&M Banking and Financial Services Practice recognize the challenges that financial institutions face while bringing the right products to market. Our reports and consulting practice provides a unique perspective allowing financial institutions to understand and strategize to achieve their product goals. Through a mix of case studies, primary research, and business modeling we provide a 360° view to identify how our clients can create, capture, and retain the value of their products and outthink the competition. Contact:
Buy Now: Anti Nicotine Therapies
Early buyers will receive 10% customization of reports
http://www.marketsandmarkets.com/Market-Reports/anti-nicotine-254.html
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategic advisory reports and serve as a business intelligence partner to Fortune 500 companies across the globe. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.
Ms. Sunita
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com
http://www.marketsandmarkets.com
http://marketsandmarkets.wordpress.com/
http://marketsandmarkets.blogspot.com/
Posted by
Unknown
on
The opulent emirate of Dubai looks like a sea of lights during the
night. A famous saying about Dubai goes that Dubai sleeps during the day
and is at its liveliest during the night. Obviously, for pub crawlers,
Dubai is a paradise. However, there are some issues with booze. Tourists
can get the cheapest booze from the airport duty free terminal. Within
Dubai, booze is limited to certain bars and nightclubs and is pretty
expensive. The booze shops are accessible only to local residents with a
booze permit. Now let’s take a whirlwind tour of some of the hottest
night haunts in the city.
Al Abaya The Palm Hotel Interchange No.5, Sheikh Zayed Rd.
This
is a great place to explore a slice of Arabic culture. The place
abounds with lip smacking Arabic cuisines and beverages to the
accompaniment of awesome song and dance sequences by local entertainers.
Irish Village
This
gem takes you on flights of fancy from Dubai to Ireland with an
ambience that magically recreates the feel of a real Irish pub. Irish
Village is one of those few places in Dubai, where can nurse a drink
without heading to some hotel bar.
Kasbar Royal Mirage Hotel
This
charmer is not to be missed. The club has three levels and celebrated
DJs belt out hauntingly melodious Arabic music. With mesmerising Arabic
style decorations, this club is an ideal place to unwind oneself.
Hard Rock Café
Part
of the world renowned global Hard Rock chain, this hip nightspot is a
hit with family crowds. Live music, food, and booze put you in the
perfect mood for some quality time.
Troyka in Century Hotel Bur Dubai and Arbat Club in Carlton Tower
Those
who have had enough of the regular pub scene and want to check out some
Russian action should definitely devote a night to these two spots.
Cyclone - Al Nasr leisure land Karama
As
non stop rock n roll assails yours senses and the electrifying
atmosphere gets you on the dance floor, you thank yourself for buying
your flight ticket to Dubai. Cyclone is also a famous pick up joint in
Dubai.
American Dream and Dawat Restaurant at Seashell Inn Hotel Burdubai
As
the name suggests, American dream is a night club with an
English/American theme, while Daawat is a restaurant that titillates
your taste buds with Indian cuisines.
About the Author
Shawn Trelly is associated with Cheap Tickets as expert writer since Five years.find availableflights to Dubai and then schedule your trip.
Posted by
a
on
categories:
|
Its location, landscape, heritage and facilities all combine to make
Surrey a much visited destination in the south east of England. You can
really have the best of both worlds when visiting Surrey. On one side
there’s the rolling Surrey hills which is an Area of Outstanding Natural
Beauty with Leith Hill being the highest point in the south of England
and the National Trust own no less than 10 properties in Surrey set in
their usual spectacular surroundings, a gardener’s paradise. On the
other side, should you need to be get to the centre of London, transport
links and shear close proximity make Surrey the ideal base.
Weybridge
is particularly well situated for visiting the capital when staying in
Surrey. Weybridge has all the facilities you would expect from great
shops and restaurants to what it is most famous for and that is home to
the Brooklands motor racing circuit. The Brooklands motor racing circuit
opened in 1907. It made history as it was the first ever purpose built
motor race circuit that was banked in the world. In Britain motorists
were restricted to a 20mph speed limit and Brooklands was so popular due
to the high speeds that could be reached. Sadly the last race was in
1939. Fortunately, this historical motor racing site has been developed
in recent years and it now home to many large retail and car companies
and most recently, a state of art hotel. Keeping the heritage of this
quite unique former motor racing site has been high on the agenda for
the new Brooklands hotel. From the original Brooklands racetrack which
rolls out before you in riven quartz and honed granite, to the
glittering 1930s inspired honeycomb pendants that greet the guests upon
check-in. For Brooklands fans, the knowing nod to the legacy of the race
circuit that surrounds and runs through the hotel is great to see. If a
stay at the hotel isn’t enough then there’s the Brooklands Museum which
not only exhibits cars and motorcycles but also aircraft.
Surrey
hotels come in forms to suit everyone from country house to state of
the art with spas and modern architecture. Even business travellers must
think staying in a hotel in Surrey isn’t really a hardship! Even though
towns like Weybridge have the following statistics, located just five
minutes from the M25 motorway, thirty minutes from central London,
seventeen miles from Heathrow and thirty three miles from Gatwick,
Weybridge and Surrey feel a million miles away from the hustle and
bustle of the capital.
So, it’s not hard to see the appeal of
Surrey and to see why this beautiful county will continue to attract
thousands of visitors each year. The popularity of the “staycation” over
the past 2 years hasn’t just been attributed to family summer holidays.
With the cost of air fares rising, poor exchange rate and tightening
purse strings, going on weekend city breaks abroad are also in decline. A
weekend away in a Surrey hotel is cheaper with far less travelling time
but most of all the enjoyment of a varied landscape and complete
relaxation.
About the Author
Brooklands Hotel - a new breed of luxury Surrey hotels.
Posted by
a
on
categories:
|
Volve, Norway, Commercial Asset Valuation and Forecast to 2013
http://www.reportsandreports.com/market-reports/volve-norway-commercial-asset-valuation-and-forecast-to-2013/
GlobalData
Norway Market Research
Volve is a small offshore field, 200km from Stavanger in Southern
Norway. The field lies at a water depth of 80m and the reserves lie at a
depth of 2,750 to 3,120m.
The field was discovered in 1993 and the development plan was approved
in 2005. The field started producing in 2008 and is expected to produce
till 2013. The total recoverable reserves are estimated at 85.6
million barrels of crude oil and 38,830 MMcf of associated gas.
Statoil Petroleum AS is the operator of the field and majority
stakeholder with 59.60% interest. The other partners include ExxonMobil
E&P Norway and Bayerngas Produksjon Norge AS.
The Volve crude oil is light sour crude with density of 29.8 ° API and
sulfur content 1.72%. The oil is produced using Maersk Inspirer Jack-up
Rig. This rig acts as drilling as well as production and processing
facility. The oil is transported using shuttle tankers, and gas through
a pipeline.
The field is expected to generate $6.3 billion in gross revenues over
its useful life of six years. The asset IRR is expected at 75.63%.
Scope
- The report provides detailed information on oil and gas production, infrastructure, reserves, geology, operator and equity partners and the latest fiscal terms applicable to the asset and provides its fair value (Remaining Net Present Value) based on remaining reserves, forecast production, capital and operational costs, fiscal regime and commodity prices.
- The report also provides additional valuation parameters like Internal Rate of Return (IRR), Profitability Index (PI), Pay Back (discounted and undiscounted), Entitlement Production (EP) and Working Interest (WI) to enhance your decision making process.
- This report provides detailed sensitivity analysis of the remaining NPV with changes in the commodity prices, discount rate, production and key fiscal terms.
- Detailed cash flows over the life of the asset are included in the report. These cash flows cover a wide range of calculations related to various payments to the government/licensing authority.
- Interactive Excel models can be used to derive custom valuations, sensitivities and cash flows based on the specific inputs by the user in the model. These custom inputs vary from production data, cost information, price information and fiscal terms information.
- Make well informed investment decisions based on detailed operational analysis and cash flow forecasts
- Estimate the fair value of your future investment under different economic and fiscal conditions
- Value a prospective investment target through a comprehensive analysis using focused forecasting and valuation methodologies.
- Supporting interactive excel model will enhance your decision making capability in a more rapid and time sensitive manner
- Evaluate how the changes in the country’s fiscal policies impact the cash flows and the present value of the asset
1.1 List of Tables 4
1.2 List of Figures 4
2 Volve, Norway, Introduction 5
3 Volve, Norway, Geology and Formation 6
4 Volve, Norway, Equity Partners 7
5 Volve, Norway, Crude Oil and Associated Gas Reserves 8
6 Volve, Norway, Key Fiscal Terms 8
6.1 Royalty 8
6.2 Fees 8
6.3 Special Petroleum Tax 9
6.4 Taxation 9
6.5 Carbon Dioxide Tax 9
6.6 Deductions and Depreciation 9
7 Volve, Norway, Infrastructure 9
7.1 Upstream Infrastructure 10
7.1.1 Jackup Rig- Maersk Inspirer 11
7.2 Midstream Infrastructure 11
7.2.1 Floating Storage Unit- Navion Saga 11
8 Volve, Norway, Development Plan 11
9 Volve, Norway, Crude Oil and Associated Gas Production 12
10 Volve, Norway, Field Economics 13
10.1 Volve, Economic Assumptions 13
10.1.1 Forecast Commodity Prices 13
10.1.2 Inflation 13
10.1.3 Discount Rate and Representation of Cash Flows 13
10.1.4 Sensitivity 13
10.1.5 Access to the Economic Model 13
10.2 Volve, Norway, Cash Flow Analysis 14
10.3 Volve, Norway, Remaining PV Sensitivity Analysis 15
10.3.1 Remaining NPV Sensitivity to Discount Rates 15
10.3.2 Remaining NPV Sensitivity to Change in Commodity Prices and Production 16
10.3.3 Remaining NPV Sensitivity to Petroleum Revenue Tax and Production Rate 17
11 Volve, Norway, Summary Cash Flows 18
11.1 Volve, Norway, Front End Load Due To Fiscal Policy 19
11.2 Volve, Norway, Tax Liability 20
12 Appendix 21
12.1 Methodology 21
12.2 Coverage 21
12.3 Secondary Research 21
12.4 Primary Research 21
12.5 E&P Forecasts 22
12.6 Capital Costs 22
12.7 Exploration and Appraisal (E&A) Costs 22
12.8 Operating Costs 23
12.9 Expert Panel Validation 23
12.10 About GlobalData
12.11 Contact Us
12.12 Disclaimer
1.1 List of Tables
Table 1: Volve, Norway, Key Asset Data, 2010 5
Table 2: Volve, Norway, Field Reserves, January 2010 8
Table 3: Volve, Norway, Development Wellbores (WB) 10
Table 4: Volve, Norway, Exploration Wellbores (WB) 11
Table 5: Volve, Norway, Historic and Forecast Production, 2008-2013 13
Table 6: Volve, Norway, Commodity Price Assumptions, 2010-2013 13
Table 7: Volve, Norway, Project Analysis Metrics, 2010 14
Table 8: Volve, Norway, Remaining PV Sensitivity Analysis Over Discount Rate Vs. Commodity Price Change, in m $ 15
Table 9: Volve, Norway, Remaining PV Sensitivity Analysis over Commodity Price Change Vs Production Rate, in m $ 16
Table 10: Volve, Norway, Remaining PV Sensitivity Analysis at 10% Discount Rate over SPT Change Vs Production Rate, in m $ 17
Table 11: Volve, Norway, Asset Summary Cash Flows, 000’$, 2006-2013 18
Table 12: Volve, Norway, Front End Load, 000’$, 2006-2013 19
Table 13: Volve, Norway, Tax Liability Estimations, 000’$, 2008-2013 20
1.2 List of Figures
Figure 1: Volve, Norway, Location Map 6
Figure 2: Volve, Norway, Illustrative Diagram of Reservoir and Geological Cross-Section 7
Figure 3: Volve, Norway, Current Equity Details, 2010 8
Figure 4: Volve, Norway, Jack-up Rig, Maersk Inspirer 10
Figure 5: Volve, Norway, Crude Oil, Historic Production and Forecast, 2008-2013 12
Figure 6: Volve, Norway, Associated Gas, Historic Production and Forecast, 2008-2013 12
Figure 7: Volve, Norway, Gross Revenue Versus Tax Cash Flow Analysis, 2006-2013 14
Figure 8: Volve, Norway, Remaining PV Sensitivity Analysis Over Discount Rate Vs. Commodity Price Change, in m $ 15
Figure 9: Volve, Norway, Remaining PV Sensitivity Analysis over Change in Production Vs. Commodity Price Change, in m $ 16
Figure 10: Volve, Norway, Remaining PV Sensitivity Analysis Over SPT rate Change Vs. Production Rate, in m $ 17
Asgard, Norway, Commercial Asset Valuation and Forecast to 2024
Posted by
a
on
categories:
|
Vilje, Norway, Commercial Asset Valuation and Forecast to 2014
http://www.reportsandreports.com/market-reports/vilje-norway-commercial-asset-valuation-and-forecast-to-2014/
GlobalData
Norway Market Research
Report Summary
Vilje field is located in the northern part of North Sea in Norway. The field is located in the block 25/4 on the Norwegian Continental Shelf. It is to the north of Heimdal Field and at a total reservoir depth of 7,446 feet. The field was discovered in the year 2003 with a gross oil column of about 223 feet.
Statoil Petroleum AS is the operator of the field with 28.85% equity stake. The other equity partners of the field are Marathon Oil Corporation and Total S.A. The field came operational in 2008. The estimated total recoverable reserves of the field as on December 2009 are 52.20 million barrels of oil.
Vilje field produces crude oil and associated gas. The crude is of 36.90 °API with 0.15% of sulfur content. The field produced about 9.67 million barrels of crude oil and 2,636.44 MMcf of associated gas in 2009.
The field life of Vilje is expected to be around seven years with complete estimated abandonment during 2014. The field is expected to generate $3.23 billion in revenue (undiscounted) during 2010-2014 and is expected to yield an IRR of around 32.22%.
Scope
Vilje field is located in the northern part of North Sea in Norway. The field is located in the block 25/4 on the Norwegian Continental Shelf. It is to the north of Heimdal Field and at a total reservoir depth of 7,446 feet. The field was discovered in the year 2003 with a gross oil column of about 223 feet.
Statoil Petroleum AS is the operator of the field with 28.85% equity stake. The other equity partners of the field are Marathon Oil Corporation and Total S.A. The field came operational in 2008. The estimated total recoverable reserves of the field as on December 2009 are 52.20 million barrels of oil.
Vilje field produces crude oil and associated gas. The crude is of 36.90 °API with 0.15% of sulfur content. The field produced about 9.67 million barrels of crude oil and 2,636.44 MMcf of associated gas in 2009.
The field life of Vilje is expected to be around seven years with complete estimated abandonment during 2014. The field is expected to generate $3.23 billion in revenue (undiscounted) during 2010-2014 and is expected to yield an IRR of around 32.22%.
Scope
- The report provides detailed information on oil and gas production, infrastructure, reserves, geology, operator and equity partners and the latest fiscal terms applicable to the asset and provides its fair value (Remaining Net Present Value) based on remaining reserves, forecast production, capital and operational costs, fiscal regime and commodity prices.
- The report also provides additional valuation parameters like Internal Rate of Return (IRR), Profitability Index (PI), Pay Back (discounted and undiscounted), Entitlement Production (EP) and Working Interest (WI) to enhance your decision making process.
- This report provides detailed sensitivity analysis of the remaining NPV with changes in the commodity prices, discount rate, production and key fiscal terms.
- Detailed cash flows over the life of the asset are included in the report. These cash flows cover a wide range of calculations related to various payments to the government/licensing authority.
- Interactive Excel models can be used to derive custom valuations, sensitivities and cash flows based on the specific inputs by the user in the model. These custom inputs vary from production data, cost information, price information and fiscal terms information.
- Make well informed investment decisions based on detailed operational analysis and cash flow forecasts
- Estimate the fair value of your future investment under different economic and fiscal conditions
- Value a prospective investment target through a comprehensive analysis using focused forecasting and valuation methodologies.
- Supporting interactive excel model will enhance your decision making capability in a more rapid and time sensitive manner
- Evaluate how the changes in the country’s fiscal policies impact the cash flows and the present value of the asset
Posted by
a
on
categories:
|
Drilling for Offshore Oil and Gas - Africa and Middle East
http://www.reportsandreports.com/market-reports/drilling-for-offshore-oil-and-gas-africa-and-middle-east/
Introduction
Offshore drilling represents nearly 50 per cent of offshore capex within the global E&P business. This report has been prepared in recognition of drilling’s importance to the turnover of almost every oil and gas company and service provider working in the sector. Drilling has a fundamental role in the location and extraction of all the oil and gas production that can be realized from offshore locations.
The report explains, quantifies and costs the offshore drilling market, providing historic drilling and spending trends and forecast trends over the period 2010 to 2014. It presents a series of estimates and forecasts for drilling and spending on all offshore wells and discusses key drilling events in each country. It also provides a regional synthesis of shallow versus deep water spending and exploratory versus development spending, and includes a broad discussion of new and improved drilling technology, looking at how this may affect the drilling spend market over subsequent years.
Key findings and highlights
Reasons to buy
Offshore drilling represents nearly 50 per cent of offshore capex within the global E&P business. This report has been prepared in recognition of drilling’s importance to the turnover of almost every oil and gas company and service provider working in the sector. Drilling has a fundamental role in the location and extraction of all the oil and gas production that can be realized from offshore locations.
The report explains, quantifies and costs the offshore drilling market, providing historic drilling and spending trends and forecast trends over the period 2010 to 2014. It presents a series of estimates and forecasts for drilling and spending on all offshore wells and discusses key drilling events in each country. It also provides a regional synthesis of shallow versus deep water spending and exploratory versus development spending, and includes a broad discussion of new and improved drilling technology, looking at how this may affect the drilling spend market over subsequent years.
Key findings and highlights
- A rounded total of 1,920 wells were drilled in Africa from 2005 to 2009, with nearly 70 per cent in West Africa and around 20 per cent in Egypt. An approximate total of 2,475 exploratory and development wells are forecast to be drilled over the next five years, with over half expected to be located in deep waters.
- A rounded total of 1,430 wells were drilled offshore the Middle East from 2005 to 2009, with 98 per cent in the Gulf, almost all of which were development wells. Around 2,000 exploratory and development wells are forecast over the next five years.
- Over the last five years it is estimated that nearly 2,500 shallow water wells were drilled in the region. Meanwhile around 1,150 deep water wells were drilled. Over the next five years it is forecast that around 3,170 shallow water wells will be drilled accompanied by around 1,310 deep water wells.
Reasons to buy
- Develop a drilling investment strategy targeted around exploration and production hotspots
- Evaluate likely technology driven growth opportunities created by the medium term evolution of the drilling sector
- Analyze how drilling spending patterns will vary between different technology sectors and geographies over a five-year forecast period
Table Of Contents
OVERVIEW
- Catalyst
- Content summary
- Methodology
EXECUTIVE SUMMARY
- Introduction
- Results and conclusions
THE TOOLS OF OFFSHORE DRILLING
- Foundations of drilling
- The offshore drilling rig
- Deep water drilling
- The current rig market
- Current global well numbers
REVIEW OF DRILLING TECHNOLOGY
- Introduction
- Exploration wells
- Appraisal wells
- Development wells
- Rotary drilling procedures
- Rotary drilling mechanics
- Services: rigs
- Services: geoscience
- Services: engineering
- Services: support
DRILLING IN AFRICA AND THE MIDDLE EAST
- Africa Introduction
- North and Northwest Africa
- West Africa
- South and East Africa
- The Middle East introduction
- Regional Drilling Summary
SPENDING IN AFRICA AND THE MIDDLE EAST
- Introduction
- The spending model
- Africa
- The Middle East
- Regional Spending Summary
INNOVATIONS IN DRILLING
- Introduction
- Evolving drilling techniques
- The longer-term future
- Conclusion
APPENDIX
- Industry abbreviations
- Data sources
- Conventions used
- Ask the analyst
- Datamonitor consulting
- Disclaimer
TABLE OF FIGURES
Figure 1: OFFSHORE DRILLING: Africa and Middle East drilling numbers 1995 to
Figure 2: OFFSHORE DRILLING: Africa and Middle East spending numbers in report period
Figure 3: Reconstruction of the Drake well in Titusville, Pennsylvania
Figure 4: Drake engine (background) and drill string/casing (foreground)
Figure 5: An early rotary drilling rig
Figure 6: Lake Caddo, site of the first well over water
Figure 7: OFFSHORE DRILLING: rig shares in the market in 2009
Figure 8: Pair of rigs on the Hibernia concrete platform
Figure 9: Drilling tender alongside a tension leg platform (TLP)
Figure 10: Drilling barge on Lake Erie
Figure 11: The Galaxy I cantilever jackup, built 1991
Figure 12: The Glomar Jack Ryan drillship, built in 2000
Figure 13: The deck and derrick of a drillship
Figure 14: The Transocean Marianas, built in
Figure 15: The riser above sea level in a semisubmersible
Posted by
a
on
categories:
|
Pharmaceutical M&A in the Asia-Pacific Region – India and China drive regional activity but Japan still dominates high value transactions
Pharmaceutical M&A in the Asia-Pacific Region – India and China drive regional activity but Japan still dominates high value transactions
http://www.reportsandreports.com/market-reports/pharmaceutical-ma-in-the-asia-pacific-region-india-and-china-/
Introduction
Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region.
Scope
Sluggish performance in the major pharmaceutical markets prompted by growing generic competition and increasing healthcare cost-containment are forcing companies to seek opportunities elsewhere. Massive populations, rapid economic growth and burgeoning middle classes make emerging Asia-Pacific markets particularly attractive to foreign companies.
Companies penetrating these markets often acquire local manufacturers and generics firms that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic industries from foreign domination.
Within the period analyzed in this report, the highest number of M&A deals involving APAC based companies was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009. Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based companies having been announced.
Reasons to Purchase
Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 “patent cliff” and slowing growth in major developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region.
Scope
- Provides an overview of the healthcare systems and pharmaceutical markets of key countries within Asia-Pacific.
- Overview of drivers, resistors and trends within the Asia-Pacific M&A landscape.
- Analysis of the types of acquisitions and healthcare sectors targeted.
- Analysis of geographic M&A activity and transaction values.
Sluggish performance in the major pharmaceutical markets prompted by growing generic competition and increasing healthcare cost-containment are forcing companies to seek opportunities elsewhere. Massive populations, rapid economic growth and burgeoning middle classes make emerging Asia-Pacific markets particularly attractive to foreign companies.
Companies penetrating these markets often acquire local manufacturers and generics firms that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic industries from foreign domination.
Within the period analyzed in this report, the highest number of M&A deals involving APAC based companies was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009. Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based companies having been announced.
Reasons to Purchase
- Gain insight into the number and scope of M&A transactions in Asia-Pacific, and key drivers and resistors.
- Identify which are the most perused pharmaceutical sectors in terms of M&A deals, and which companies have been the most acquisitive in recent years.
- Identify which markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma.
Table Of Contents
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global issue reports: 2
About the Healthcare Asia-Pacific Team 3
1. Executive Summary 4
Strategic scoping and focus 4
Key findings 5
Key definitions 6
Company classifications 6
Acquisition types 6
Geographic classifications 7
Other 7
Related reports 8
Upcoming related reports 8
Table of Contents 9
2. Overview of the APAC pharmaceutical markets 10
Key findings 10
Gaining government drug reimbursement is the key to success in Australia 12
Government participation in healthcare 12
Key health concerns 12
Pharmaceutical market structure 13
Chinese healthcare reforms continue to improve market access 15
Government participation in healthcare 15
Key health concerns 16
Pharmaceutical market structure 16
Hong Kong operates separately from mainland China 18
Indian government investments are needed to improve local market attractiveness 20
Government participation in healthcare 20
Key health concerns 21
Pharmaceutical market structure 21
Indonesia is still far from becoming a truly attractive market 23
Government participation in healthcare 23
Key health concerns 24
Pharmaceutical market structure 24
The Japanese market is well-established and highly regulated 26
Government participation in healthcare 26
Key health concerns 26
Pharmaceutical market structure 27
Malaysia is a rising star within APAC 29
Government participation in healthcare 29
Key health concerns 29
Pharmaceutical market structure 29
New Zealand offers only limited growth and a small market 32
Government participation in healthcare 32
Key health concerns 32
Pharmaceutical market structure 32
The Philippines is a poor nation still struggling to provide affordable healthcare access 35
Government participation in healthcare 35
Key health concerns 36
Pharmaceutical market structure 36
High-quality healthcare is available in the established Singaporean market 38
Government participation in healthcare 38
Key health concerns 38
Pharmaceutical market structure 38
South Korea is relatively lucrative, but can be tricky to navigate 41
Government participation in healthcare 41
Key health concerns 41
Pharmaceutical market structure 42
Taiwan's regulatory environment is improving but still has some way to go 44
Government participation in healthcare 44
Key health concerns 44
Pharmaceutical market structure 45
Thailand's large public sector is tightly controlled by the government 47
Government participation in healthcare 47
Key health concerns 48
Pharmaceutical market structure 48
The pharmaceutical drug market grows amid a poor healthcare system in Vietnam 50
Government participation in healthcare 50
Key health concerns 51
Pharmaceutical market structure 51
3. Overview of M&A activity 53
Key findings 53
Drivers and resistors of APAC M&A 56
Stronger growth forecast in emerging compared to developed markets 57
Big Pharma look to emerging markets to replace lost revenue as the patent cliff threatens blockbuster sales 58
Product development costs are rising rapidly in developed markets, particularly for clinical trials 59
Changing socio-demographics create patient demand for better healthcare 59
Policy and regulation changes are creating a more certain business environment in APAC markets 61
Overview of M&A activity by geography 62
China was the most common target location for acquisitions by APAC-based companies 63
China was the most common location of APAC-based acquiring companies 63
India holds the greatest interest for leading pharma companies in terms of acquisition prospects 64
Half of all M&A deals involved both APAC-based acquirers and targets only 65
Overview of M&A activity by deal type and size 67
100% acquisitions are the principal deal type involving APAC companies 67
Majority acquisitions are a favored strategy of large generics players 68
Few minority acquisitions are pursued in APAC 68
Acquisitions of complete business units are the most common form of asset purchase 69
Many buyouts were performed by existing shareholders 70
M&A value was highest in 2008 70
Overview of M&A activity by healthcare sector and therapy area 74
Pharmaceutical manufacturers are the most common APAC M&A targets 74
Leading pharma players have preferences for specific sectors 78
Acquirers target highest value and volume therapeutic areas 79
4. Country specific M&A activity 81
Key findings 81
Australia had a strong start to 2010 82
M&A summary 84
China showed mainly domestic M&A activity, although international deals are on the rise 85
M&A summary 87
M&A activity in India was particularly high in 2008, then dropped off again 88
M&A summary 90
Japan saw biggest deal of the region when it purchased Indian generics company in 2008 91
M&A summary 93
Most Malaysian M&A deals involved the broader healthcare industry 94
M&A summary 95
M&A activity in New Zealand slowed down considerably in 2009-10 96
M&A summary 97
Singaporean companies were particularly active as acquirers 98
M&A summary 99
M&A activity in South Korea is increasing consistently 100
M&A summary 101
The majority of M&A deals in Taiwan took place in 2008 102
M&A summary 103
Other APAC countries were involved in few M&A deals from Q1 2007-Q1 2010 104
Indonesia 104
Philippines 104
Thailand 105
Vietnam 105
Significant M&A in APAC has continued throughout the first half of 2010 106
Abbott acquires formulations business of India's leading pharmaceutical firm 106
Indian pharmaceutical industry grows wary of multinational dominance 106
GlaxoSmithKline focuses on small acquisitions in emerging markets 107
GlaxoSmithKline invests in South Korea 108
GlaxoSmithKline cannot find value in Indian acquisitions 108
Chinese CRO deal falters 108
International players continue to expand presence in APAC through means other than M&A 109
5. Bibliography 110
Publications and online articles 110
Company press releases 116
Datamonitor products 118
APPENDIX 119
Methodology 119
Key definitions 120
Company classifications 120
Acquisition types 120
Geographic classifications 121
Other 121
Exchange rates 121
About Datamonitor 122
About Datamonitor Healthcare 122
Datamonitor consulting 122
Disclaimer 124
List of Tables
Table 1: Comparison of key health indicators in the South-East Asian and Western Pacific regions with global indicators, 2006-08 11
Table 2: Australia - key demographic and health indicators, 2006-08 14
Table 3: China - key demographic and health indicators, 2006-08 18
Table 4: India: key demographic and health indicators, 2005-08 22
Table 5: Indonesia: key demographic and health indicators, 2005-08 25
Table 6: Japan: key demographic and health indicators, 2006-08 28
Table 7: Malaysia: key demographic and health indicators, 2006-08 31
Table 8: New Zealand: key demographic and health indicators, 2006-08 34
Table 9: Philippines: key demographic and health indicators, 2004-08 37
Table 10: Singapore: key demographic and health indicators, 2006-08 40
Table 11: South Korea: key demographic and health indicators, 2006-08 43
Table 12: Taiwan: key demographic and health indicators, 2001-2010 46
Table 13: Thailand: key demographic and health indicators, 2002-08 49
Table 14: Vietnam: key demographic and health indicators, 2006-08 52
Table 15: APAC - Top 10 highest value M&A deals, Q1 2007-Q1 2010 73
Table 16: APAC - focus of target companies acquired in M&A deals involving APAC-based companies, Q1 2007-Q1 2010 76
Table 17: Australia - summary of key M&A deals, Q1 2007-Q1 2010 84
Table 18: China and Hong Kong - summary of key M&A deals, Q1 2007-Q1 2010 87
Table 19: India - summary of key M&A deals, Q1 2007-Q1 2010 90
Table 20: Japan - summary of key M&A deals, Q1 2007-Q1 2010 93
Table 21: Malaysia - summary of key M&A deals, Q1 2007-Q1 2010 95
Table 22: New Zealand - summary of key M&A deals, Q1 2007-Q1 2010 97
Table 23: Singapore -summary of key M&A deals, Q1 2007-Q1 2010 99
Table 24: South Korea -summary of key M&A deals, Q1 2007-Q1 2010 101
Table 25: Taiwan -summary of key M&A deals, Q1 2007-Q1 2010 103
Table 26: Exchange rates to US dollars, July 8, 2010 121
List of Figures
Figure 1: Map of Asia-Pacific (APAC) region 7
Figure 2: Drivers and resistors of pharmaceutical growth in the emerging markets, 2010 53
Figure 3: APAC - total number of M&A deals by quarter and year, Q1 2007-Q1 2010 54
Figure 4: APAC - pharma M&A activity strategic rationale and future outlook, 2010 56
Figure 5: Forecast pharmaceutical sales growth (for the top 50 companies in 2009) for the main four geographic regions worldwide, 2009-2014 57
Figure 6: Deficit in global annual sales for the top 50 pharma companies (excluding generics companies) due to generic erosion of brands facing patent expiry from 2010 onwards, 2010-14 58
Figure 7: APAC - growth in gross domestic product (GDP) of Malaysia, Thailand, China, Indonesia, Philippines and Vietnam, 2004-08 60
Figure 8: APAC - M&A mix (acquirer/target) by quarter, Q1 2007-Q1 2010 62
Figure 9: APAC - key locations of M&A targets sought by APAC-based acquirers, Q1 2007-Q1 2010 63
Figure 10: APAC - key locations of acquirers seeking APAC-based targets for M&A, Q1 2007-Q1 2010 64
Figure 11: APAC - M&A deals targeting APAC-based companies and involving leading global pharmaceutical companies or their direct subsidiaries by year, Q1 2007-Q1 2010 65
Figure 12: APAC - role of APAC-based companies in M&A deals, Q1 2007-Q1 2010 66
Figure 13: APAC - Deal type by quarter, Q1 2007-Q1 2010 67
Figure 14: APAC - M&A by deal type, Q1 2007-Q1 2010 69
Figure 15: APAC - M&A deals by value range, Q1 2007-Q1 2010 71
Figure 16: APAC - value of M&A deals by quarter, Q1 2007-Q1 2010 72
Figure 17: APAC - primary industry of M&A targets by region, Q1 2007-Q1 2010 75
Figure 18: APAC - focus of M&A by location and development status, Q1 2007-Q1 2010 77
Figure 19: APAC - target sectors of M&A deals by company sales rank, Q1 2007-Q1 2010 78
Figure 20: APAC - therapeutic focus of target companies for M&A deals involving APAC-based companies, Q1 2007-Q1 2010 79
Figure 21: Australia - number and value of M&A transactions by acquirer/target location and year, Q1 2007-Q1 2010 83
Figure 22: China and Hong Kong - role of Chinese companies in M&A transactions by year, Q1 2007-Q1 2010 86
Figure 23: China and Hong Kong - leading sectors targeted in M&A transactions, Q1 2007-Q1 2010 86
Figure 24: India - International markets targeted by Indian acquirers by year, Q1 2007-Q1 2010 89
Figure 25: India - most prolific Indian acquirers by target sector, Q1 2007-Q1 2010 89
Figure 26: Japan - foreign targets acquired by Japanese firms by country of headquarters, Q1 2007-Q1 2010 92
Figure 27: Japan - value of M&A involving Japanese companies by value range, Q1 2007-Q1 2010 92
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global issue reports: 2
About the Healthcare Asia-Pacific Team 3
1. Executive Summary 4
Strategic scoping and focus 4
Key findings 5
Key definitions 6
Company classifications 6
Acquisition types 6
Geographic classifications 7
Other 7
Related reports 8
Upcoming related reports 8
Table of Contents 9
2. Overview of the APAC pharmaceutical markets 10
Key findings 10
Gaining government drug reimbursement is the key to success in Australia 12
Government participation in healthcare 12
Key health concerns 12
Pharmaceutical market structure 13
Chinese healthcare reforms continue to improve market access 15
Government participation in healthcare 15
Key health concerns 16
Pharmaceutical market structure 16
Hong Kong operates separately from mainland China 18
Indian government investments are needed to improve local market attractiveness 20
Government participation in healthcare 20
Key health concerns 21
Pharmaceutical market structure 21
Indonesia is still far from becoming a truly attractive market 23
Government participation in healthcare 23
Key health concerns 24
Pharmaceutical market structure 24
The Japanese market is well-established and highly regulated 26
Government participation in healthcare 26
Key health concerns 26
Pharmaceutical market structure 27
Malaysia is a rising star within APAC 29
Government participation in healthcare 29
Key health concerns 29
Pharmaceutical market structure 29
New Zealand offers only limited growth and a small market 32
Government participation in healthcare 32
Key health concerns 32
Pharmaceutical market structure 32
The Philippines is a poor nation still struggling to provide affordable healthcare access 35
Government participation in healthcare 35
Key health concerns 36
Pharmaceutical market structure 36
High-quality healthcare is available in the established Singaporean market 38
Government participation in healthcare 38
Key health concerns 38
Pharmaceutical market structure 38
South Korea is relatively lucrative, but can be tricky to navigate 41
Government participation in healthcare 41
Key health concerns 41
Pharmaceutical market structure 42
Taiwan's regulatory environment is improving but still has some way to go 44
Government participation in healthcare 44
Key health concerns 44
Pharmaceutical market structure 45
Thailand's large public sector is tightly controlled by the government 47
Government participation in healthcare 47
Key health concerns 48
Pharmaceutical market structure 48
The pharmaceutical drug market grows amid a poor healthcare system in Vietnam 50
Government participation in healthcare 50
Key health concerns 51
Pharmaceutical market structure 51
3. Overview of M&A activity 53
Key findings 53
Drivers and resistors of APAC M&A 56
Stronger growth forecast in emerging compared to developed markets 57
Big Pharma look to emerging markets to replace lost revenue as the patent cliff threatens blockbuster sales 58
Product development costs are rising rapidly in developed markets, particularly for clinical trials 59
Changing socio-demographics create patient demand for better healthcare 59
Policy and regulation changes are creating a more certain business environment in APAC markets 61
Overview of M&A activity by geography 62
China was the most common target location for acquisitions by APAC-based companies 63
China was the most common location of APAC-based acquiring companies 63
India holds the greatest interest for leading pharma companies in terms of acquisition prospects 64
Half of all M&A deals involved both APAC-based acquirers and targets only 65
Overview of M&A activity by deal type and size 67
100% acquisitions are the principal deal type involving APAC companies 67
Majority acquisitions are a favored strategy of large generics players 68
Few minority acquisitions are pursued in APAC 68
Acquisitions of complete business units are the most common form of asset purchase 69
Many buyouts were performed by existing shareholders 70
M&A value was highest in 2008 70
Overview of M&A activity by healthcare sector and therapy area 74
Pharmaceutical manufacturers are the most common APAC M&A targets 74
Leading pharma players have preferences for specific sectors 78
Acquirers target highest value and volume therapeutic areas 79
4. Country specific M&A activity 81
Key findings 81
Australia had a strong start to 2010 82
M&A summary 84
China showed mainly domestic M&A activity, although international deals are on the rise 85
M&A summary 87
M&A activity in India was particularly high in 2008, then dropped off again 88
M&A summary 90
Japan saw biggest deal of the region when it purchased Indian generics company in 2008 91
M&A summary 93
Most Malaysian M&A deals involved the broader healthcare industry 94
M&A summary 95
M&A activity in New Zealand slowed down considerably in 2009-10 96
M&A summary 97
Singaporean companies were particularly active as acquirers 98
M&A summary 99
M&A activity in South Korea is increasing consistently 100
M&A summary 101
The majority of M&A deals in Taiwan took place in 2008 102
M&A summary 103
Other APAC countries were involved in few M&A deals from Q1 2007-Q1 2010 104
Indonesia 104
Philippines 104
Thailand 105
Vietnam 105
Significant M&A in APAC has continued throughout the first half of 2010 106
Abbott acquires formulations business of India's leading pharmaceutical firm 106
Indian pharmaceutical industry grows wary of multinational dominance 106
GlaxoSmithKline focuses on small acquisitions in emerging markets 107
GlaxoSmithKline invests in South Korea 108
GlaxoSmithKline cannot find value in Indian acquisitions 108
Chinese CRO deal falters 108
International players continue to expand presence in APAC through means other than M&A 109
5. Bibliography 110
Publications and online articles 110
Company press releases 116
Datamonitor products 118
APPENDIX 119
Methodology 119
Key definitions 120
Company classifications 120
Acquisition types 120
Geographic classifications 121
Other 121
Exchange rates 121
About Datamonitor 122
About Datamonitor Healthcare 122
Datamonitor consulting 122
Disclaimer 124
List of Tables
Table 1: Comparison of key health indicators in the South-East Asian and Western Pacific regions with global indicators, 2006-08 11
Table 2: Australia - key demographic and health indicators, 2006-08 14
Table 3: China - key demographic and health indicators, 2006-08 18
Table 4: India: key demographic and health indicators, 2005-08 22
Table 5: Indonesia: key demographic and health indicators, 2005-08 25
Table 6: Japan: key demographic and health indicators, 2006-08 28
Table 7: Malaysia: key demographic and health indicators, 2006-08 31
Table 8: New Zealand: key demographic and health indicators, 2006-08 34
Table 9: Philippines: key demographic and health indicators, 2004-08 37
Table 10: Singapore: key demographic and health indicators, 2006-08 40
Table 11: South Korea: key demographic and health indicators, 2006-08 43
Table 12: Taiwan: key demographic and health indicators, 2001-2010 46
Table 13: Thailand: key demographic and health indicators, 2002-08 49
Table 14: Vietnam: key demographic and health indicators, 2006-08 52
Table 15: APAC - Top 10 highest value M&A deals, Q1 2007-Q1 2010 73
Table 16: APAC - focus of target companies acquired in M&A deals involving APAC-based companies, Q1 2007-Q1 2010 76
Table 17: Australia - summary of key M&A deals, Q1 2007-Q1 2010 84
Table 18: China and Hong Kong - summary of key M&A deals, Q1 2007-Q1 2010 87
Table 19: India - summary of key M&A deals, Q1 2007-Q1 2010 90
Table 20: Japan - summary of key M&A deals, Q1 2007-Q1 2010 93
Table 21: Malaysia - summary of key M&A deals, Q1 2007-Q1 2010 95
Table 22: New Zealand - summary of key M&A deals, Q1 2007-Q1 2010 97
Table 23: Singapore -summary of key M&A deals, Q1 2007-Q1 2010 99
Table 24: South Korea -summary of key M&A deals, Q1 2007-Q1 2010 101
Table 25: Taiwan -summary of key M&A deals, Q1 2007-Q1 2010 103
Table 26: Exchange rates to US dollars, July 8, 2010 121
List of Figures
Figure 1: Map of Asia-Pacific (APAC) region 7
Figure 2: Drivers and resistors of pharmaceutical growth in the emerging markets, 2010 53
Figure 3: APAC - total number of M&A deals by quarter and year, Q1 2007-Q1 2010 54
Figure 4: APAC - pharma M&A activity strategic rationale and future outlook, 2010 56
Figure 5: Forecast pharmaceutical sales growth (for the top 50 companies in 2009) for the main four geographic regions worldwide, 2009-2014 57
Figure 6: Deficit in global annual sales for the top 50 pharma companies (excluding generics companies) due to generic erosion of brands facing patent expiry from 2010 onwards, 2010-14 58
Figure 7: APAC - growth in gross domestic product (GDP) of Malaysia, Thailand, China, Indonesia, Philippines and Vietnam, 2004-08 60
Figure 8: APAC - M&A mix (acquirer/target) by quarter, Q1 2007-Q1 2010 62
Figure 9: APAC - key locations of M&A targets sought by APAC-based acquirers, Q1 2007-Q1 2010 63
Figure 10: APAC - key locations of acquirers seeking APAC-based targets for M&A, Q1 2007-Q1 2010 64
Figure 11: APAC - M&A deals targeting APAC-based companies and involving leading global pharmaceutical companies or their direct subsidiaries by year, Q1 2007-Q1 2010 65
Figure 12: APAC - role of APAC-based companies in M&A deals, Q1 2007-Q1 2010 66
Figure 13: APAC - Deal type by quarter, Q1 2007-Q1 2010 67
Figure 14: APAC - M&A by deal type, Q1 2007-Q1 2010 69
Figure 15: APAC - M&A deals by value range, Q1 2007-Q1 2010 71
Figure 16: APAC - value of M&A deals by quarter, Q1 2007-Q1 2010 72
Figure 17: APAC - primary industry of M&A targets by region, Q1 2007-Q1 2010 75
Figure 18: APAC - focus of M&A by location and development status, Q1 2007-Q1 2010 77
Figure 19: APAC - target sectors of M&A deals by company sales rank, Q1 2007-Q1 2010 78
Figure 20: APAC - therapeutic focus of target companies for M&A deals involving APAC-based companies, Q1 2007-Q1 2010 79
Figure 21: Australia - number and value of M&A transactions by acquirer/target location and year, Q1 2007-Q1 2010 83
Figure 22: China and Hong Kong - role of Chinese companies in M&A transactions by year, Q1 2007-Q1 2010 86
Figure 23: China and Hong Kong - leading sectors targeted in M&A transactions, Q1 2007-Q1 2010 86
Figure 24: India - International markets targeted by Indian acquirers by year, Q1 2007-Q1 2010 89
Figure 25: India - most prolific Indian acquirers by target sector, Q1 2007-Q1 2010 89
Figure 26: Japan - foreign targets acquired by Japanese firms by country of headquarters, Q1 2007-Q1 2010 92
Figure 27: Japan - value of M&A involving Japanese companies by value range, Q1 2007-Q1 2010 92
Posted by
a
on
categories:
|
Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake
http://www.reportsandreports.com/market-reports/japan-pharmaceutical-market-overview-regulatory-reforms-will-sti/
Introduction
The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma include the growing use of chronic high-value innovative treatments driven by an increasingly elderly population, the high proportion of the healthcare budget spent on pharmaceuticals compared to other developed pharmaceutical markets, and the low level of generic penetration.
Scope
Korosho determines the reimbursable drug price in Japan which is added to the National Health Insurance (NHI) list which must be followed by all insurers. The few non-reimbursed prescription drug groups include oral contraceptives, lifestyle drugs, and some vaccines.
Korosho implemented guidance for biosimilars approval in March 2009 and since then two biosimilars have been launched in Japan. Although this is a positive step for the biosimilars industry, the conservative and brand-loyal nature in Japan means that uptake will be slow, with only the larger, more well known players likely to succeed.
In contrast to the bleak prospects pervading the other major markets, Japan seems to have a brighter outlook with pharma companies having been less affected by job cuts and site closures.
Reasons to Purchase
The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma include the growing use of chronic high-value innovative treatments driven by an increasingly elderly population, the high proportion of the healthcare budget spent on pharmaceuticals compared to other developed pharmaceutical markets, and the low level of generic penetration.
Scope
- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Japan
- Assesses the size of Japan's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
- Examines Japan's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
- Quantifies Japan's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Korosho determines the reimbursable drug price in Japan which is added to the National Health Insurance (NHI) list which must be followed by all insurers. The few non-reimbursed prescription drug groups include oral contraceptives, lifestyle drugs, and some vaccines.
Korosho implemented guidance for biosimilars approval in March 2009 and since then two biosimilars have been launched in Japan. Although this is a positive step for the biosimilars industry, the conservative and brand-loyal nature in Japan means that uptake will be slow, with only the larger, more well known players likely to succeed.
In contrast to the bleak prospects pervading the other major markets, Japan seems to have a brighter outlook with pharma companies having been less affected by job cuts and site closures.
Reasons to Purchase
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Japan.
- Quantify the size and growth of the prescription pharmaceutical market in Japan, analyzing key therapy areas, brands and companies.
- Assess drivers and resistors of generic and biosimilars uptake in Japan as well as the level of erosion brands can expect to face post patent expiry.
Posted by
a
on
categories:
|
Drilling for Offshore Oil and Gas (Global)
http://www.reportsandreports.com/market-reports/drilling-for-offshore-oil-and-gas-global/
Introduction
Offshore drilling represents nearly 50% of offshore capex within the global E&P business. This report has been prepared in recognition of drilling's importance to the turnover of almost every oil and gas company and service provider working in the sector. Drilling has a fundamental role in the location and extraction of all the oil and gas production that can be realized from offshore locations.
Scope of this research
Global offshore drilling activity will be fully recovered by 2011. It will stabilise in 2010, will return to growth in 2011 and will grow rapidly in the subsequent two years.
The prospects for the recovery in drilling numbers vary considerably across geographic regions, with deepwater drilling continuing to be the main driver for expanding levels of activity in the market.
Nearly 18,000 offshore wells were drilled around the world over the last five years, with numbers peaking in 2007. Around $291 billion was spent on this activity. The amount of spend is likely to grow by at least 25% over the period to 2014.
Key reasons to purchase this research
Offshore drilling represents nearly 50% of offshore capex within the global E&P business. This report has been prepared in recognition of drilling's importance to the turnover of almost every oil and gas company and service provider working in the sector. Drilling has a fundamental role in the location and extraction of all the oil and gas production that can be realized from offshore locations.
Scope of this research
- Insight on the global drilling services market and its evolution in the current environment from both an operational and expenditure perspective.
- Forecasts of the number of wells to be drilled by region and the likely level of expenditure required to fulfil predicted levels of activity.
- An overview of drilling equipment and processes and a description of how the associated technologies are costed and allocated to various well types.
- Analysis of individual offshore areas and their role in the future growth of the drilling sector and rig market.
Global offshore drilling activity will be fully recovered by 2011. It will stabilise in 2010, will return to growth in 2011 and will grow rapidly in the subsequent two years.
The prospects for the recovery in drilling numbers vary considerably across geographic regions, with deepwater drilling continuing to be the main driver for expanding levels of activity in the market.
Nearly 18,000 offshore wells were drilled around the world over the last five years, with numbers peaking in 2007. Around $291 billion was spent on this activity. The amount of spend is likely to grow by at least 25% over the period to 2014.
Key reasons to purchase this research
- Develop a drilling investment strategy targeted around Exploration and Production hotspots.
- Evaluate likely technology driven growth opportunities created by the medium term evolution of the drilling sector.
- Analyse how drilling spending patterns will vary between different technology sectors and geographies over a five-year forecast period.
Posted by
a
on
categories:
|
Commercial Insight: Inflammatory Bowel Disease Future market prospects rely on addressing cost and safety
Commercial Insight: Inflammatory Bowel Disease Future market prospects rely on addressing cost and safety
http://www.reportsandreports.com/market-reports/commercial-insight-inflammatory-bowel-disease-future-market-pr/
Introduction
New drug launches, combined with the impending impact from the seminal SONIC study, which will result in Crohn's disease patients receiving biologics in combination with immunomodulators earlier in therapy, and increased use of biologics in ulcerative colitis will help to drive sales from $3.5 billion in 2009 to $5.6 billion in 2019 across the seven major markets.
Scope
Leading on from the SONIC study, experts would like to treat IBD aggressively, but need longer-term safety data and information on which patients will be best to treat with the approach. Clearly, not every patient will be appropriate, with safety and cost and reimbursement coming to the fore.
Datamonitor has always maintained that patient preference, convenience and compliance will help determine the commercial success of marketed products for IBD. In addition, experts interviewed by Datamonitor expect the next 5 to 10 years will revolve around cost and side effects.
Recent data presented at DDW 2010 highlighted Humira's poor efficacy in ulcerative colitis, fuelling concerns over the drug's future potential in this additional indication. Datamonitor, however, remains optimistic that Humira's second Phase III study will generate positive data leading to US and EU approval in 2011.
Reasons to Purchase
New drug launches, combined with the impending impact from the seminal SONIC study, which will result in Crohn's disease patients receiving biologics in combination with immunomodulators earlier in therapy, and increased use of biologics in ulcerative colitis will help to drive sales from $3.5 billion in 2009 to $5.6 billion in 2019 across the seven major markets.
Scope
- In-depth analysis of the current and future inflammatory bowel disease market across the US, 5EU and Japanese markets, and a Rest of World snapshot
- Crohn's disease and ulcerative colitis specific sales forecasts for key brands to 2019, and total brand figure to benchmark indication-specific sales
- Detailed brand dynamics discussion, including analysis of the anti-TNFs Remicade, Humira, Cimzia and 5-aminosalicylates, such as Lialda
- Insight and analysis of the strategies of the key developers in the IBD market
Leading on from the SONIC study, experts would like to treat IBD aggressively, but need longer-term safety data and information on which patients will be best to treat with the approach. Clearly, not every patient will be appropriate, with safety and cost and reimbursement coming to the fore.
Datamonitor has always maintained that patient preference, convenience and compliance will help determine the commercial success of marketed products for IBD. In addition, experts interviewed by Datamonitor expect the next 5 to 10 years will revolve around cost and side effects.
Recent data presented at DDW 2010 highlighted Humira's poor efficacy in ulcerative colitis, fuelling concerns over the drug's future potential in this additional indication. Datamonitor, however, remains optimistic that Humira's second Phase III study will generate positive data leading to US and EU approval in 2011.
Reasons to Purchase
- Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
- Understand IBD market trends and assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
- Access a case study assessing the likelihood of ulcerative colitis approval for Humira and Simponi with three alternative scenario forecasts
Table Of Contents
OVERVIEW 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Inflammation & Immunology pharmaceutical analysis team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the inflammatory bowel disease market 3
Related reports 5
Upcoming related reports 5
Table of Contents 6
1. MARKET DEFINITION 7
Market definition for this report 7
Datamonitor adopts a different drug class definition in its latest 2010 IBD report 7
ICD-10 codes used to define the inflammatory bowel disease indications 8
Crohn's disease 8
Ulcerative colitis 9
IMS assumptions 9
Diagnosis value (DV) 9
US 11
Japan 11
5EU 12
2. MARKET OVERVIEW 14
Seven major markets 15
Current and future market overview 15
Cost and safety will dictate future of the market 15
The US will remain the largest inflammatory bowel disease market in terms of sales to 2019 17
Specific antirheumatic agents sales experienced staggering uptake and will continue to be a growth driver 17
Key impacting events in the seven major inflammatory bowel disease markets from 2010-19 18
Inflammatory bowel disease constitutes up to 30% of total brand sales in the seven major markets 19
Opportunities and threats 25
Opportunities 1: SONIC trial impact 26
Opportunities 2: testing for drug serum and antibody levels in Crohn's disease 27
Opportunities 3: biomarkers to predict response to therapies 29
Opportunities 4: new therapies in development for IBD 30
Threat 1: pricing pressure across the seven major markets 31
Threat 2: biosimilar MAbs looking more certain 31
US 33
Current and future market assessment 33
Opportunities and threats 37
Opportunity 1: US healthcare reform set to boost number of insured IBD patients 37
Opportunity 2: 12-year market exclusivity favors innovator products 38
Threat 1: US healthcare reform brings biologics approval pathway 38
Threat 2: FDA tightens marketing controls in the US 39
Japan 39
Current and future market assessment 39
Impact from exchange rates on US dollar market value in Japan 40
Opportunities and threats 42
Opportunity 1: MHLW approval timelines speeding up significantly 43
Opportunity 2: among the highest inflammatory bowel disease diagnosis rates in the major markets 43
Opportunity 3: novel Japanese provisions protect some drugs from regular price cuts 43
Opportunity 4: Japan's inflammatory bowel disease market has significant room for expansion 44
Threat 1: despite certain protection measures, future Japanese government drug price cuts remain a reality 44
Threat 2: Japan aims to increase generic market's volume share to 30% by 2012 44
Five major European markets (5EU) 45
Current and future market assessment 45
Impact from exchange rates on US dollar market value in the 5EU 46
Opportunities and threats 50
Opportunity 1: 2010 ECCO guidelines include a new section on loss of response to anti-TNFs 51
Opportunity 2: NICE recommends Humira for Crohn's disease 52
Threat 1: drug price cuts across the five major EU markets 52
Threat 2: always a risk that NICE will not recommend biologics in Crohn's disease or ulcerative colitis 53
Threat 3: Europe's biosimilar approval pathway 53
France 53
Current and future market assessment 53
Impact from exchange rates on US dollar market value in France 54
Germany 57
Current and future market assessment 57
Impact from exchange rates on US dollar market value in Germany 58
Italy 62
Current and future market assessment 62
Impact from exchange rates on US dollar market value in Italy 63
Spain 66
Current and future market assessment 66
Impact from exchange rates on US dollar market value in Spain 67
UK 70
Current and future market assessment 70
Impact from exchange rates on US dollar market value in the UK 71
Rest of the world snapshot 74
Current market assessment 75
Exceptional growth in the global inflammatory bowel disease market 75
All other EU countries dominate sales and volume, while Turkey shows impressive growth 78
Notable impact from exchange rates on US dollar market value 80
BRIC shows highest growth from 2008 to 2009 80
3. BRAND DYNAMICS 82
Overview of competitive landscape 82
Patient acquisition process 83
Introduction 83
Patient care path 83
Crohn's disease 83
Ulcerative colitis 85
Drivers of brand choice 87
Patient preference, cost and mode of delivery are among drivers of brand choice for anti-TNFs 88
US formulary tier status for leading brands 88
Notable formulary tier changes since 2008 89
Relative newcomer Cimzia shows moderate formulary advantage in 2010 90
Older 5-aminosalicylate brands show signs of slipping tier status 91
Trends in marketing strategies 91
Centocor Ortho Biotech - promoting experience and the SONIC study 92
Abbott - promoting the Humira pen device and long-term data 93
UCB - despite a low key presence, the major focus was on long-term remission 94
Shire - FDA letter dampens Pentasa and Lialda promotional plans 95
Salix - Apriso loses out to Xifaxan promotion 96
Alaven Pharmaceutical - launch of the Rowasa Kit 97
Rowasa's sales value showed an increase in 2009 after years of generic erosion 97
Rowasa Kit is more expensive than standard Rowasa 99
Anti-tumor necrosis factors (TNFs) 100
Remicade (infliximab; Centocor Ortho Biotech, Merck & Co., Mitsubishi Tanabe) 100
Drug profile 100
Absence of new clinical data for Remicade at DDW 2010, means SONIC gets the most attention 101
Filed for ulcerative colitis in Japan in June 2009 - approved in June 2010 102
SWOT analysis 103
Brand forecast to 2019 103
Humira (adalimumab; Abbott, Eisai) 110
Drug profile 110
Ulcerative colitis data not entirely positive 110
Abbott/Eisai filed Humira for Crohn's disease in Japan in September 2009 113
NICE recommends Humira for Crohn's disease 114
SWOT analysis 115
Brand forecast to 2019 116
Cimzia (certolizumab; UCB, Otsuka Pharmaceuticals) 118
Drug profile 118
Cimzia's major focus on showing long-term maintenance data and mucosal healing at DDW 2010 119
Monthly dosing schedule in Crohn's disease is coming under the spotlight 120
Cimzia out of EU development - removed from our EU forecast 121
Otsuka close to filing Cimzia for Crohn's disease in Japan 121
Early development in ulcerative colitis begins 122
SWOT analysis 123
Brand forecast to 2019 124
Integrin inhibitors 126
Tysabri (natalizumab; Elan, Biogen Idec) 126
Drug profile 126
Crohn's disease-specific sales estimations, 2009 127
Risk stratification could be one way to turn around Tysabri's fortunes in Crohn's disease 127
SWOT analysis 128
Brand forecast to 2019 129
5-aminosalicylates 130
Asacol/Asacol HD (mesalazine; Warner Chilcott, Zeria, Kyowa Hakko Kogyo) 130
Drug profile 130
Impact from competition in the US - increase in price for Asacol 400mg 131
Warner Chilcott receives Paragraph IV from Par Pharmaceuticals - generic impact to Asacol maintained 132
Zeria Pharmaceutical launched Asacol in Japan for ulcerative colitis 133
Some evidence that Asacol 3.6g is superior to Pentasa 2.25g 135
Development in Crohn's disease in Japan pushed back from Phase III to Phase I prompting removal from Datamonitor's Japanese forecast 137
SWOT analysis 137
Brand forecast to 2019 137
Pentasa (mesalazine; Ferring, Shire, Nisshin Kyorin) 138
Drug profile 138
Warning letter from FDA over promotional activity in the US 139
SWOT analysis 141
Brand forecast to 2019 142
Lialda (mesalazine MMX, Cosmo, Giuliani, Mochida, Shire) 144
Drug profile 144
Warning letter from FDA over promotional activity 145
Shire terminated US co-marketing agreement with Takeda in 2009 147
Plenty of data and promotion leads Lialda to outshine Apriso at DDW 2010 147
Paragraph IV filed by Zydus Cadila in May 2010 - potential impact to brand sales from early generics 148
Mochida Pharma put Lialda into Phase I development for ulcerative colitis - Datamonitor removes Lialda from Japanese forecast 149
SWOT analysis 149
Brand forecast to 2019 150
Apriso/Salofalk/Salofalk Granustix/AJG501 (mesalazine; Ajinomoto, Dr Falk Pharma, Salix Pharmaceuticals) 152
Drug profile 152
No substantial data presented for Apriso at the DDW 2010 153
Salix expects similar Apriso uptake to its other ulcerative colitis brand Colazal 153
Ajinomoto progressed Apriso/Salofalk into Phase III 154
SWOT analysis 156
Brand forecast to 2019 157
Other brands 158
Giazo (balsalazide disodium 1.1g tablet; Salix Pharmaceuticals) 158
After a tempestuous regulatory history, Giazo will launch in 2010, but will not exceed sales of $20m 158
Budenofalk (budesonide; Dr Falk Pharma, Salix Pharmaceuticals) 160
Datamonitor forecasts budesonide foam to launch in the US by 2012 160
Datamonitor forecasts Budenofalk's EU sales to reach $30m at the end of the forecast period 161
Entocort EC (budesonide; Prometheus, AstraZeneca) 162
Price per standard unit increase bolsters 2009 sales 162
Teva and AstraZeneca reach deal on generic Entocort EC 164
4. KEY DEVELOPERS 166
Strategic overview 166
Recent strategic partnerships/deals 167
GlaxoSmithKline exercises option to advance ChemoCentryx's Traficet-EN 167
Warner Chilcott acquired P&G pharmaceutical portfolio 167
Santarus and Ferring sign deal to develop Cosmo Pharmaceuticals's budesonide MMX 168
Trends in corporate strategy 168
Collaboration, licensing arrangements and acquisition are the main strategic corporate trends 168
Ajinomoto 168
Centocor Ortho Biotech 169
Salix Pharmaceuticals 171
Shire 172
Cosmo Pharmaceuticals 173
Warner Chilcott 174
US mesalazine market breakdown by company 175
Scenario forecast - impact on Asacol's US sales in absence of generic competition 176
5. CASE STUDIES 178
Biologics in ulcerative colitis - alternative market scenarios 178
Anti-TNF biologics in ulcerative colitis - Remicade is the major player, but competition is on the way 178
Three alternative scenarios tested involving non-approval for either Simponi or Humira, or non-approval for both 181
Conclusion 182
BIBLIOGRAPHY 185
Journal papers 185
Websites 186
Datamonitor reports 190
Other 191
APPENDIX A - MARKET ASSUMPTIONS 192
Forecasting assumptions 192
New product launches 192
Data definitions, limitations and assumptions 192
Standard units 192
Country group definitions 192
Derivation of sales forecasts and pricing trends 192
Exchange rates 192
Forecast methodology 193
APPENDIX B 194
Contributing experts 194
Conferences attended 194
Report methodology 194
About Datamonitor 194
About Datamonitor Healthcare 194
About the Immunology & Inflammation analysis team 195
Disclaimer 196
List of Tables
Table 1: Summary of therapeutic classes in inflammatory bowel disease by Anatomical Therapeutic Chemical (ATC) code, 2009 8
Table 2: Datamonitor's definition of Crohn's disease, 2010 9
Table 3: Datamonitor's definition of ulcerative colitis, 2010 9
Table 4: Gastroenterologist breakdown by region for IMS Prescribing Insights data, 2009 11
Table 5: Key events that will impact inflammatory bowel disease across the seven major markets between 2010 and 2019 19
Table 6: Sales forecasts in inflammatory bowel disease in the seven major markets ($m), split by indication, 2009-2019 21
Table 7: Opportunities and threats in the seven major inflammatory bowel disease markets, 2010 25
Table 8: Estimated patent expiry dates for the key biologics approved for the treatment of inflammatory bowel disease, 2010 32
Table 9: Sales forecasts in inflammatory bowel disease in the US ($m), split by indication, 2009-2019 35
Table 10: Opportunities and threats for inflammatory bowel disease in the US, 2010 37
Table 11: Sales forecasts in inflammatory bowel disease in Japan ($m), split by indication, 2009-2019 42
Table 12: Opportunities and threats for inflammatory bowel disease in Japan, 2010 43
Table 13: Sales forecasts in inflammatory bowel disease in the five major EU markets ($m), split by indication, 2009-2019 48
Table 14: Opportunities and threats for inflammatory bowel disease in the five major EU markets, 2010 51
Table 15: Sales forecasts in inflammatory bowel disease in France ($m), split by indication, 2009-2019 56
Table 16: Sales forecasts in inflammatory bowel disease in Germany ($m), split by indication, 2009-2019 60
Table 17: Sales forecasts in inflammatory bowel disease in Italy ($m), split by indication, 2009-2019 65
Table 18: Sales forecasts in inflammatory bowel disease in Spain ($m), split by indication, 2009-2019 69
Table 19: Sales forecasts in inflammatory bowel disease in the UK ($m), split by indication, 2009-2019 73
Table 20: Key late-stage pipeline products in development for inflammatory bowel disease (IBD), 2010 82
Table 21: Formulary status for leading brands used to treat inflammatory bowel disease in the US, 2010 89
Table 22: Remicade (infliximab) - drug profile, 2010 101
Table 23: Humira (adalimumab) - drug profile, 2010 110
Table 24: Clinical trial data for Humira (adalimumab) in ulcerative colitis, 2010 111
Table 25: Cimzia (certolizumab) - drug profile, 2010 119
Table 26: Tysabri (natalizumab) - drug profile, 2010 127
Table 27: Asacol/Asacol HD(mesalazine) - drug profile, 2010 131
Table 28: Dosing of Asacol and Pentasa tablets in ulcerative colitis in Japan, 2010 136
Table 29: Pentasa (mesalazine) - drug profile, 2010 139
Table 30: Lialda (mesalazine MMX) - drug profile, 2010 145
Table 31: Apriso/Salofalk (mesalazine) - drug profile, 2010 153
Table 32: Leading companies in the inflammatory bowel disease in the seven major markets, 2009-2019 167
Table 33: Centocor Ortho Biotech: key marketed drugs and R&D pipeline for inflammatory bowel disease (IBD), 2010 170
Table 34: Cosmo Pharmaceuticals: key marketed drugs and R&D pipeline for inflammatory bowel disease (IBD), 2010 174
Table 35: Comparison between Remicade, Simponi and Humira across characteristics, including efficacy, safety, formulation and cost, in ulcerative colitis, 2010 180
Table 36: Sales ($m) of Remicade (infliximab), Simponi (golimumab) and Humira (adalimumab) in ulcerative colitis in the combined US and five major EU markets, under Datamonitor's base assumption and three alternative scenarios, 2009-2019 184
Table 37: Currency exchange rates, 2010 193
List of Figures
Figure 93: Methodology for forecasting price to remove impact of currency fluctuations on future trend 193
OVERVIEW 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Inflammation & Immunology pharmaceutical analysis team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the inflammatory bowel disease market 3
Related reports 5
Upcoming related reports 5
Table of Contents 6
1. MARKET DEFINITION 7
Market definition for this report 7
Datamonitor adopts a different drug class definition in its latest 2010 IBD report 7
ICD-10 codes used to define the inflammatory bowel disease indications 8
Crohn's disease 8
Ulcerative colitis 9
IMS assumptions 9
Diagnosis value (DV) 9
US 11
Japan 11
5EU 12
2. MARKET OVERVIEW 14
Seven major markets 15
Current and future market overview 15
Cost and safety will dictate future of the market 15
The US will remain the largest inflammatory bowel disease market in terms of sales to 2019 17
Specific antirheumatic agents sales experienced staggering uptake and will continue to be a growth driver 17
Key impacting events in the seven major inflammatory bowel disease markets from 2010-19 18
Inflammatory bowel disease constitutes up to 30% of total brand sales in the seven major markets 19
Opportunities and threats 25
Opportunities 1: SONIC trial impact 26
Opportunities 2: testing for drug serum and antibody levels in Crohn's disease 27
Opportunities 3: biomarkers to predict response to therapies 29
Opportunities 4: new therapies in development for IBD 30
Threat 1: pricing pressure across the seven major markets 31
Threat 2: biosimilar MAbs looking more certain 31
US 33
Current and future market assessment 33
Opportunities and threats 37
Opportunity 1: US healthcare reform set to boost number of insured IBD patients 37
Opportunity 2: 12-year market exclusivity favors innovator products 38
Threat 1: US healthcare reform brings biologics approval pathway 38
Threat 2: FDA tightens marketing controls in the US 39
Japan 39
Current and future market assessment 39
Impact from exchange rates on US dollar market value in Japan 40
Opportunities and threats 42
Opportunity 1: MHLW approval timelines speeding up significantly 43
Opportunity 2: among the highest inflammatory bowel disease diagnosis rates in the major markets 43
Opportunity 3: novel Japanese provisions protect some drugs from regular price cuts 43
Opportunity 4: Japan's inflammatory bowel disease market has significant room for expansion 44
Threat 1: despite certain protection measures, future Japanese government drug price cuts remain a reality 44
Threat 2: Japan aims to increase generic market's volume share to 30% by 2012 44
Five major European markets (5EU) 45
Current and future market assessment 45
Impact from exchange rates on US dollar market value in the 5EU 46
Opportunities and threats 50
Opportunity 1: 2010 ECCO guidelines include a new section on loss of response to anti-TNFs 51
Opportunity 2: NICE recommends Humira for Crohn's disease 52
Threat 1: drug price cuts across the five major EU markets 52
Threat 2: always a risk that NICE will not recommend biologics in Crohn's disease or ulcerative colitis 53
Threat 3: Europe's biosimilar approval pathway 53
France 53
Current and future market assessment 53
Impact from exchange rates on US dollar market value in France 54
Germany 57
Current and future market assessment 57
Impact from exchange rates on US dollar market value in Germany 58
Italy 62
Current and future market assessment 62
Impact from exchange rates on US dollar market value in Italy 63
Spain 66
Current and future market assessment 66
Impact from exchange rates on US dollar market value in Spain 67
UK 70
Current and future market assessment 70
Impact from exchange rates on US dollar market value in the UK 71
Rest of the world snapshot 74
Current market assessment 75
Exceptional growth in the global inflammatory bowel disease market 75
All other EU countries dominate sales and volume, while Turkey shows impressive growth 78
Notable impact from exchange rates on US dollar market value 80
BRIC shows highest growth from 2008 to 2009 80
3. BRAND DYNAMICS 82
Overview of competitive landscape 82
Patient acquisition process 83
Introduction 83
Patient care path 83
Crohn's disease 83
Ulcerative colitis 85
Drivers of brand choice 87
Patient preference, cost and mode of delivery are among drivers of brand choice for anti-TNFs 88
US formulary tier status for leading brands 88
Notable formulary tier changes since 2008 89
Relative newcomer Cimzia shows moderate formulary advantage in 2010 90
Older 5-aminosalicylate brands show signs of slipping tier status 91
Trends in marketing strategies 91
Centocor Ortho Biotech - promoting experience and the SONIC study 92
Abbott - promoting the Humira pen device and long-term data 93
UCB - despite a low key presence, the major focus was on long-term remission 94
Shire - FDA letter dampens Pentasa and Lialda promotional plans 95
Salix - Apriso loses out to Xifaxan promotion 96
Alaven Pharmaceutical - launch of the Rowasa Kit 97
Rowasa's sales value showed an increase in 2009 after years of generic erosion 97
Rowasa Kit is more expensive than standard Rowasa 99
Anti-tumor necrosis factors (TNFs) 100
Remicade (infliximab; Centocor Ortho Biotech, Merck & Co., Mitsubishi Tanabe) 100
Drug profile 100
Absence of new clinical data for Remicade at DDW 2010, means SONIC gets the most attention 101
Filed for ulcerative colitis in Japan in June 2009 - approved in June 2010 102
SWOT analysis 103
Brand forecast to 2019 103
Humira (adalimumab; Abbott, Eisai) 110
Drug profile 110
Ulcerative colitis data not entirely positive 110
Abbott/Eisai filed Humira for Crohn's disease in Japan in September 2009 113
NICE recommends Humira for Crohn's disease 114
SWOT analysis 115
Brand forecast to 2019 116
Cimzia (certolizumab; UCB, Otsuka Pharmaceuticals) 118
Drug profile 118
Cimzia's major focus on showing long-term maintenance data and mucosal healing at DDW 2010 119
Monthly dosing schedule in Crohn's disease is coming under the spotlight 120
Cimzia out of EU development - removed from our EU forecast 121
Otsuka close to filing Cimzia for Crohn's disease in Japan 121
Early development in ulcerative colitis begins 122
SWOT analysis 123
Brand forecast to 2019 124
Integrin inhibitors 126
Tysabri (natalizumab; Elan, Biogen Idec) 126
Drug profile 126
Crohn's disease-specific sales estimations, 2009 127
Risk stratification could be one way to turn around Tysabri's fortunes in Crohn's disease 127
SWOT analysis 128
Brand forecast to 2019 129
5-aminosalicylates 130
Asacol/Asacol HD (mesalazine; Warner Chilcott, Zeria, Kyowa Hakko Kogyo) 130
Drug profile 130
Impact from competition in the US - increase in price for Asacol 400mg 131
Warner Chilcott receives Paragraph IV from Par Pharmaceuticals - generic impact to Asacol maintained 132
Zeria Pharmaceutical launched Asacol in Japan for ulcerative colitis 133
Some evidence that Asacol 3.6g is superior to Pentasa 2.25g 135
Development in Crohn's disease in Japan pushed back from Phase III to Phase I prompting removal from Datamonitor's Japanese forecast 137
SWOT analysis 137
Brand forecast to 2019 137
Pentasa (mesalazine; Ferring, Shire, Nisshin Kyorin) 138
Drug profile 138
Warning letter from FDA over promotional activity in the US 139
SWOT analysis 141
Brand forecast to 2019 142
Lialda (mesalazine MMX, Cosmo, Giuliani, Mochida, Shire) 144
Drug profile 144
Warning letter from FDA over promotional activity 145
Shire terminated US co-marketing agreement with Takeda in 2009 147
Plenty of data and promotion leads Lialda to outshine Apriso at DDW 2010 147
Paragraph IV filed by Zydus Cadila in May 2010 - potential impact to brand sales from early generics 148
Mochida Pharma put Lialda into Phase I development for ulcerative colitis - Datamonitor removes Lialda from Japanese forecast 149
SWOT analysis 149
Brand forecast to 2019 150
Apriso/Salofalk/Salofalk Granustix/AJG501 (mesalazine; Ajinomoto, Dr Falk Pharma, Salix Pharmaceuticals) 152
Drug profile 152
No substantial data presented for Apriso at the DDW 2010 153
Salix expects similar Apriso uptake to its other ulcerative colitis brand Colazal 153
Ajinomoto progressed Apriso/Salofalk into Phase III 154
SWOT analysis 156
Brand forecast to 2019 157
Other brands 158
Giazo (balsalazide disodium 1.1g tablet; Salix Pharmaceuticals) 158
After a tempestuous regulatory history, Giazo will launch in 2010, but will not exceed sales of $20m 158
Budenofalk (budesonide; Dr Falk Pharma, Salix Pharmaceuticals) 160
Datamonitor forecasts budesonide foam to launch in the US by 2012 160
Datamonitor forecasts Budenofalk's EU sales to reach $30m at the end of the forecast period 161
Entocort EC (budesonide; Prometheus, AstraZeneca) 162
Price per standard unit increase bolsters 2009 sales 162
Teva and AstraZeneca reach deal on generic Entocort EC 164
4. KEY DEVELOPERS 166
Strategic overview 166
Recent strategic partnerships/deals 167
GlaxoSmithKline exercises option to advance ChemoCentryx's Traficet-EN 167
Warner Chilcott acquired P&G pharmaceutical portfolio 167
Santarus and Ferring sign deal to develop Cosmo Pharmaceuticals's budesonide MMX 168
Trends in corporate strategy 168
Collaboration, licensing arrangements and acquisition are the main strategic corporate trends 168
Ajinomoto 168
Centocor Ortho Biotech 169
Salix Pharmaceuticals 171
Shire 172
Cosmo Pharmaceuticals 173
Warner Chilcott 174
US mesalazine market breakdown by company 175
Scenario forecast - impact on Asacol's US sales in absence of generic competition 176
5. CASE STUDIES 178
Biologics in ulcerative colitis - alternative market scenarios 178
Anti-TNF biologics in ulcerative colitis - Remicade is the major player, but competition is on the way 178
Three alternative scenarios tested involving non-approval for either Simponi or Humira, or non-approval for both 181
Conclusion 182
BIBLIOGRAPHY 185
Journal papers 185
Websites 186
Datamonitor reports 190
Other 191
APPENDIX A - MARKET ASSUMPTIONS 192
Forecasting assumptions 192
New product launches 192
Data definitions, limitations and assumptions 192
Standard units 192
Country group definitions 192
Derivation of sales forecasts and pricing trends 192
Exchange rates 192
Forecast methodology 193
APPENDIX B 194
Contributing experts 194
Conferences attended 194
Report methodology 194
About Datamonitor 194
About Datamonitor Healthcare 194
About the Immunology & Inflammation analysis team 195
Disclaimer 196
List of Tables
Table 1: Summary of therapeutic classes in inflammatory bowel disease by Anatomical Therapeutic Chemical (ATC) code, 2009 8
Table 2: Datamonitor's definition of Crohn's disease, 2010 9
Table 3: Datamonitor's definition of ulcerative colitis, 2010 9
Table 4: Gastroenterologist breakdown by region for IMS Prescribing Insights data, 2009 11
Table 5: Key events that will impact inflammatory bowel disease across the seven major markets between 2010 and 2019 19
Table 6: Sales forecasts in inflammatory bowel disease in the seven major markets ($m), split by indication, 2009-2019 21
Table 7: Opportunities and threats in the seven major inflammatory bowel disease markets, 2010 25
Table 8: Estimated patent expiry dates for the key biologics approved for the treatment of inflammatory bowel disease, 2010 32
Table 9: Sales forecasts in inflammatory bowel disease in the US ($m), split by indication, 2009-2019 35
Table 10: Opportunities and threats for inflammatory bowel disease in the US, 2010 37
Table 11: Sales forecasts in inflammatory bowel disease in Japan ($m), split by indication, 2009-2019 42
Table 12: Opportunities and threats for inflammatory bowel disease in Japan, 2010 43
Table 13: Sales forecasts in inflammatory bowel disease in the five major EU markets ($m), split by indication, 2009-2019 48
Table 14: Opportunities and threats for inflammatory bowel disease in the five major EU markets, 2010 51
Table 15: Sales forecasts in inflammatory bowel disease in France ($m), split by indication, 2009-2019 56
Table 16: Sales forecasts in inflammatory bowel disease in Germany ($m), split by indication, 2009-2019 60
Table 17: Sales forecasts in inflammatory bowel disease in Italy ($m), split by indication, 2009-2019 65
Table 18: Sales forecasts in inflammatory bowel disease in Spain ($m), split by indication, 2009-2019 69
Table 19: Sales forecasts in inflammatory bowel disease in the UK ($m), split by indication, 2009-2019 73
Table 20: Key late-stage pipeline products in development for inflammatory bowel disease (IBD), 2010 82
Table 21: Formulary status for leading brands used to treat inflammatory bowel disease in the US, 2010 89
Table 22: Remicade (infliximab) - drug profile, 2010 101
Table 23: Humira (adalimumab) - drug profile, 2010 110
Table 24: Clinical trial data for Humira (adalimumab) in ulcerative colitis, 2010 111
Table 25: Cimzia (certolizumab) - drug profile, 2010 119
Table 26: Tysabri (natalizumab) - drug profile, 2010 127
Table 27: Asacol/Asacol HD(mesalazine) - drug profile, 2010 131
Table 28: Dosing of Asacol and Pentasa tablets in ulcerative colitis in Japan, 2010 136
Table 29: Pentasa (mesalazine) - drug profile, 2010 139
Table 30: Lialda (mesalazine MMX) - drug profile, 2010 145
Table 31: Apriso/Salofalk (mesalazine) - drug profile, 2010 153
Table 32: Leading companies in the inflammatory bowel disease in the seven major markets, 2009-2019 167
Table 33: Centocor Ortho Biotech: key marketed drugs and R&D pipeline for inflammatory bowel disease (IBD), 2010 170
Table 34: Cosmo Pharmaceuticals: key marketed drugs and R&D pipeline for inflammatory bowel disease (IBD), 2010 174
Table 35: Comparison between Remicade, Simponi and Humira across characteristics, including efficacy, safety, formulation and cost, in ulcerative colitis, 2010 180
Table 36: Sales ($m) of Remicade (infliximab), Simponi (golimumab) and Humira (adalimumab) in ulcerative colitis in the combined US and five major EU markets, under Datamonitor's base assumption and three alternative scenarios, 2009-2019 184
Table 37: Currency exchange rates, 2010 193
List of Figures
Figure 93: Methodology for forecasting price to remove impact of currency fluctuations on future trend 193
Posted by
a
on
categories:
|
Cytotoxic Therapies Market Forecast
http://www.reportsandreports.com/market-reports/cytotoxic-therapies-market-forecast/
Introduction
The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs' success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Reasons to Purchase
The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs' success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Reasons to Purchase
- Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
Posted by
a
on
categories:
|
Inflammatory Bowel Disease Market Forecast
http://www.reportsandreports.com/market-reports/inflammatory-bowel-disease-market-forecast/
Introduction
This model provides detailed sales and volume forecast data for the inflammatory bowel disease market. Including Crohn's disease and ulcerative colitis market sizing, within the context of total brand sales across the seven major markets.
Reasons to Purchase
http://www.reportsandreports.com/market-reports/inflammatory-bowel-disease-market-forecast/
Introduction
This model provides detailed sales and volume forecast data for the inflammatory bowel disease market. Including Crohn's disease and ulcerative colitis market sizing, within the context of total brand sales across the seven major markets.
Reasons to Purchase
- Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
- Understand IBD market trends and assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
- Access a case study assessing the likelihood of ulcerative colitis approval for Humira and Simponi with three alternative scenario forecasts
Posted by
a
on
categories:
|
Google map
Source: fiveprime
Posted by
a
on
categories:
|
